penicillamine has been researched along with Leukopenia in 23 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral chelation therapy with d-penicillamine (d-PCN) has been proven to be effective in the treatment of mild-to-moderate lead poisoning." | 9.09 | Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning. ( Shannon, MW; Townsend, MK, 2000) |
| "After a controlled, double blind multicenter trial of D-penicillamine in the treatment of rheumatoid arthritis, 148 patients were followed for an additional year in an open label trial." | 9.06 | Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis. Cooperative Systematic Studies of Rheumatic Disease Group. ( , 1987) |
| "In a retrospective cohort study we reviewed our experience using D-penicillamine in children with low-level lead poisoning (whole blood lead levels 25 to 40 micrograms/dL) to determine its efficacy and the incidence of side effects." | 7.67 | Efficacy and toxicity of D-penicillamine in low-level lead poisoning. ( Graef, J; Lovejoy, FH; Shannon, M, 1988) |
| "HLA phenotype frequencies were studied in 21 rheumatoid arthritis (RA) patients with haematotoxic reactions to aurothioglucose (AuTG) or D-penicillamine (DP), 65 matched RA controls and 277 healthy controls." | 7.67 | HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. ( Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1985) |
| "One hundred fourteen patients with definite or classic rheumatoid arthritis were followed prospectively between January 1976 and April 1981 to monitor their toxicity pattern to D-penicillamine." | 7.66 | Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. ( Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982) |
| "The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years." | 5.32 | Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. ( Akisu, M; Aydogdu, S; Kultursay, N; Ozgenc, F; Yagci, RV; Yalaz, M, 2003) |
| "Oral chelation therapy with d-penicillamine (d-PCN) has been proven to be effective in the treatment of mild-to-moderate lead poisoning." | 5.09 | Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning. ( Shannon, MW; Townsend, MK, 2000) |
| "After a controlled, double blind multicenter trial of D-penicillamine in the treatment of rheumatoid arthritis, 148 patients were followed for an additional year in an open label trial." | 5.06 | Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis. Cooperative Systematic Studies of Rheumatic Disease Group. ( , 1987) |
| "In a retrospective cohort study we reviewed our experience using D-penicillamine in children with low-level lead poisoning (whole blood lead levels 25 to 40 micrograms/dL) to determine its efficacy and the incidence of side effects." | 3.67 | Efficacy and toxicity of D-penicillamine in low-level lead poisoning. ( Graef, J; Lovejoy, FH; Shannon, M, 1988) |
| "HLA phenotype frequencies were studied in 21 rheumatoid arthritis (RA) patients with haematotoxic reactions to aurothioglucose (AuTG) or D-penicillamine (DP), 65 matched RA controls and 277 healthy controls." | 3.67 | HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. ( Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1985) |
| "One hundred fourteen patients with definite or classic rheumatoid arthritis were followed prospectively between January 1976 and April 1981 to monitor their toxicity pattern to D-penicillamine." | 3.66 | Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. ( Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982) |
| "The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years." | 1.32 | Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. ( Akisu, M; Aydogdu, S; Kultursay, N; Ozgenc, F; Yagci, RV; Yalaz, M, 2003) |
| " Adverse effects occurred more frequently after rapid increases in dosage." | 1.27 | The toxicity of D-penicillamine in systemic sclerosis. ( Blair, S; Medsger, TA; Steen, VD, 1986) |
| "Children suffering from juvenile chronic arthritis need a longterm therapy and guidance for many years." | 1.27 | [Chronic juvenile arthritis. Control of long-term therapy]. ( Tulzer, W, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (91.30) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| STERNLIEB, I | 1 |
| SCHEINBERG, IH | 1 |
| Yalaz, M | 1 |
| Aydogdu, S | 1 |
| Ozgenc, F | 1 |
| Akisu, M | 1 |
| Kultursay, N | 1 |
| Yagci, RV | 1 |
| Kean, WF | 2 |
| Lock, CJ | 1 |
| Howard-Lock, HE | 1 |
| Buchanan, WW | 1 |
| Krel', AA | 1 |
| Kanevskaia, MZ | 1 |
| Rashchupkina, ZP | 1 |
| Bolotin, EV | 1 |
| Chichasova, NV | 1 |
| Anastassiades, TP | 1 |
| Dwosh, IL | 1 |
| Ford, PM | 1 |
| Kelly, WG | 1 |
| Dok, CM | 1 |
| Negishi, M | 1 |
| Sato, H | 1 |
| Sekine, F | 1 |
| Mita, S | 1 |
| Ono, I | 1 |
| Kobayashi, K | 1 |
| Oseto, Y | 1 |
| Hamai, T | 1 |
| Takahashi, T | 1 |
| Shannon, MW | 1 |
| Townsend, MK | 1 |
| Colombo, B | 1 |
| Gerloni, V | 1 |
| Kuntz, JL | 1 |
| Mansilla, D | 1 |
| Pasquali, JL | 1 |
| Asch, L | 1 |
| Davis, P | 1 |
| Bleehen, SS | 1 |
| Hammond, WP | 1 |
| Miller, JE | 1 |
| Starkebaum, G | 1 |
| Zweerink, HJ | 1 |
| Rosenthal, AS | 1 |
| Dale, DC | 1 |
| Steen, VD | 1 |
| Blair, S | 1 |
| Medsger, TA | 1 |
| Batlle Gualda, E | 1 |
| Shannon, M | 1 |
| Graef, J | 1 |
| Lovejoy, FH | 1 |
| Speerstra, F | 1 |
| Reekers, P | 1 |
| van de Putte, LB | 1 |
| Vandenbroucke, JP | 1 |
| Tulzer, W | 1 |
| Stacher, A | 1 |
| Alexander, M | 1 |
| Wille, G | 1 |
| Werner, T | 1 |
| Weinmann, HM | 1 |
| Day, AT | 1 |
| Camus, JP | 1 |
| Crouzet, J | 1 |
| Guillien, P | 1 |
| Benichou, C | 1 |
| Lievre, JA | 1 |
| Fulghum, DD | 1 |
| Katz, R | 1 |
5 reviews available for penicillamine and Leukopenia
| Article | Year |
|---|---|
[Penicillamine: its use in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Evaluation; Female; Fever; Gastrointestinal | 1979 |
[Spontaneous septic arthritides during rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Arthritis, Infectious; Arthritis, Rheumatoid; Gold; Humans; Immunity, Cellu | 1977 |
D-penicillamine in the treatment of rheumatoid arthritis and progressive systemic sclerosis.
Topics: Animals; Arthritis, Rheumatoid; Chelating Agents; Collagen; Copper; Humans; Leukopenia; Nephrotic Sy | 1976 |
[Auranofin and aurothiomalate sodium: a comparative review (and II) Efficacy, tolerance and safety].
Topics: Anemia; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Clinical Trials as Topic; Diarrhea; Drug | 1985 |
[10 years of penicillamine].
Topics: Cystinuria; Drug Eruptions; Gold; Hepatolenticular Degeneration; Humans; Lead Poisoning; Leukopenia; | 1966 |
4 trials available for penicillamine and Leukopenia
| Article | Year |
|---|---|
Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning.
Topics: Adolescent; Blood Cell Count; Chelating Agents; Child; Child, Preschool; Drug Eruptions; Female; Hum | 2000 |
Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis. Cooperative Systematic Studies of Rheumatic Disease Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Drug | 1987 |
[Auranofin and aurothiomalate sodium: a comparative review (and II) Efficacy, tolerance and safety].
Topics: Anemia; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Clinical Trials as Topic; Diarrhea; Drug | 1985 |
[100 cases of common rheumatoid polyarthritis, treated with D-penicillamin].
Topics: Adult; Aged; Antibody Specificity; Arthritis, Rheumatoid; Clinical Trials as Topic; Copper; Dyspepsi | 1974 |
15 other studies available for penicillamine and Leukopenia
| Article | Year |
|---|---|
PENICILLAMINE THERAPY FOR HEPATOLENTICULAR DEGENERATION.
Topics: Amenorrhea; Avitaminosis; Bone and Bones; Copper; Desensitization, Immunologic; Diet; Drug Eruptions | 1964 |
Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy.
Topics: Chelating Agents; Female; Fetal Diseases; Hepatolenticular Degeneration; Humans; Infant, Newborn; Le | 2003 |
Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Drug Eruptions; Drug Interactions; Dysgeusia; | 1982 |
[Chlorbutin, azathioprine, D-penicillamine, and levamisole (Decaris) in the treatment of rheumatoid arthritis patients. I. Comparative analysis of side effects].
Topics: Arthritis, Rheumatoid; Azathioprine; Bronchial Spasm; Chlorambucil; Drug Eruptions; Dyspepsia; Human | 1981 |
Efficacy and toxicity of D-penicillamine for rheumatoid disease in the elderly.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Drug Eruptions; Female; Gastrointestinal Diseases; | 1982 |
[A case of rheumatoid arthritis associated with leukocytopenia during D-penicillamine treatment].
Topics: Arthritis, Rheumatoid; Female; Humans; Leukopenia; Middle Aged; Penicillamine | 1982 |
Suppression of in vitro granulocytopoiesis by captopril and penicillamine.
Topics: Animals; Bone Marrow; Captopril; Catalase; Cells, Cultured; Colony-Forming Units Assay; Dogs; Enalap | 1988 |
The toxicity of D-penicillamine in systemic sclerosis.
Topics: Arthritis, Rheumatoid; Digestive System Diseases; Dose-Response Relationship, Drug; Drug Eruptions; | 1986 |
Efficacy and toxicity of D-penicillamine in low-level lead poisoning.
Topics: Adolescent; Child; Child, Preschool; Humans; Infant; Lead; Lead Poisoning; Leukopenia; Penicillamine | 1988 |
HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aurothioglucose; Female; Gene Frequency; Gold; Histocompatibilit | 1985 |
[Chronic juvenile arthritis. Control of long-term therapy].
Topics: Adrenal Cortex Hormones; Alopecia; Anti-Inflammatory Agents; Arthritis, Juvenile; Child; Child, Pres | 1985 |
[Immunosuppressive therapy in hematology].
Topics: Adrenal Cortex Hormones; Adult; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Anemia, Myelophthis | 1972 |
[D-penicillamine therapy in liver diseases. Preliminary results in 44 cases].
Topics: Adult; Aged; Chronic Disease; Female; Hepatitis; Humans; Leukopenia; Liver Cirrhosis; Liver Diseases | 1974 |
Penicillamine in the hands of the family doctor.
Topics: Albuminuria; Arthritis, Rheumatoid; Blood Platelet Disorders; Follow-Up Studies; Humans; Leukopenia; | 1974 |
Penicillamine for scleroderma.
Topics: Animals; Drug Hypersensitivity; Feeding and Eating Disorders; Humans; Joint Diseases; Leukopenia; Pe | 1968 |